Company
(location)

Type of
financing

Number of
shares, units
or warrants
(M)

Amount
raised
(M)

Investors; placement agents; details

 

Date

TOTAL: $688.69M

Agile Therapeutics Inc. (Princeton, N.J.)

Private placement of common stock

3.4S

$20

Agile entered a definitive stock purchase agreement with a group of institutional accredited investors, including both existing and new investors, for the private placement of 3.4M shares of common stock at $5.85 per share to raise $20M

1/21/15

Aldeyra Therapeutics Inc. (Lexington, Mass.)

Private placement of common stock and warrants

1.1S and W for 1.1S

$7.79

Aldeyra entered a definitive purchase agreement to raise approximately $7.79M in a private placement of 1.1M shares of common stock at $7 each, and warrants to purchase up to 1.1M shares of common stock at an exercise price of $9.50; the placement was led by Perceptive Advisors LLC, with participation by Knoll Capital, Sphera Global Healthcare Fund, DAFNA Capital and other accredited investors; Laidlaw & Co. (UK) Ltd. is acting as sole placement agent

1/14/15

Aldeyra Therapeutics Inc. (Lexington, Mass.)

Private placement of common stock and a warrant

0.212S and W for 0.212S

$2

Aldeyra closed a $2M private placement, selling 211,528 shares of common stock at a price of $9.33 per share and a warrant to purchase up to 211,528 shares of common stock at a price of 12.5 cents per share; the placement is in addition to the $7.79M private placement on Jan. 16

1/23/15

Alnylam Pharmaceuticals Inc. (Cambridge, Mass.)

Private placement of common stock

0.647S

$61.5

Genzyme Corp. exercised its right to purchase 647,448 shares of common stock, the number of shares needed to maintain its current 12% ownership; this is being done concurrently with the $450M public offering at the price of $95 per share

1/22/15

Amarantus Bioscience Holdings Inc. (San Francisco)

Series E preferred stock offering

N/A

$1

Amarantus entered agreements to complete its Series E preferred stock offering by raising an additional $1M, bringing the total funds raised to $6M

1/13/15

Arch Biopartners Inc. (Toronto)

Private placement of units

2.1U

$0.75

Arch Biopartners intends to complete a nonbrokered private placement offering of up to 2.1M units priced at 35 cents each for gross proceeds of up to $750,050

1/7/15

Bind Therapeutics Inc. (Cambridge, Mass.)

Credit facility

N/A

$15

Bind Therapeutics entered an amendment of its existing credit facility from Hercules Technology III LP, an affiliate of Hercules Technology Growth Capital, to borrow an additional $15M in growth capital, less the repayment of the outstanding balance on the company's existing term loan facility of approximately $3M

1/25/15

Brainstorm Cell Therapeutics Inc. (Petach Tikvah, Israel)

Warrant exercise

N/A

$13

Brainstorm Cell will raise gross proceeds of about $13M through a new warrant exercise agreement with certain holders of warrants issued in its June 13, 2014, private placement

1/9/15

Capricor Therapeutics Inc. (Los Angeles)

Private placement

ND

$10

Capricor raised $10M, placing common stock with select investors at $3.52 each; participants in the transaction included Cedars-Sinai Medical Center, Cureduchenne Ventures LLC and several directors and officers of the company

1/13/15

Celator Pharmaceuticals Inc. (Ewing, N.J.)

Sale of net operating losses

N/A

$1.94

Celator raised $1.94M from the sale of net operating losses under the New Jersey Technology Business Tax Certificate Transfer Program for the year 2014

1/6/15

Cerulean Pharma Inc. (Cambridge, Mass.)

Term loan and private placement

0.136S

$16

Cerulean entered an agreement with Hercules Technology Growth Capital Inc. for a term loan of up to $26M and a private placement of $1M of Cerulean common stock in the form of 135,501 unregistered shares at $7.38 apiece; a first tranche of $15M was funded and Cerulean can draw one additional tranche of up to $5M and another of up to $6M prior to Dec. 15; Cerulean also issued Hercules a warrant to purchase 171,901 common shares at an exercise price of $6.05 apiece

1/12/15

Cortendo AB (Göteborg, Sweden, and Radnor, Pa.)

Private placement

N/A

$27.5

Cortendo raised up to $27.5M in a private placement led by RA Capital Management, New Enterprise Associates and Broadfin Capital, and including Healthcap; the financing expands an $11M PIPE announced last October, bringing the total amount raised to $38.5M

1/14/15

D-Pharm Ltd. (Rehovot, Israel)

Public rights issue

N/A

$3.25

D-Pharm completed a public rights issue, of NIS12.8M (US$3.25M); the largest shareholder, CLAL Biotechnology (CBI), exercised all its rights to the tune of NIS8.7M and a third of the total funds raised were from the public

1/22/15

Endonovo Therapeutics Inc. (Los Angeles)

Equity purchase agreement

N/A

$3

Endonovo entered a $3M equity purchase agreement with Kodiak Capital Group LLC

1/22/15

Invivo Therapeutics Holdings Corp. (Cambridge, Mass.)

Registered direct offering

N/A

$12

Invivo received commitments from two dedicated health care funds to purchase an aggregate of $12M of the company's common stock in a registered direct offering of 8M common stock shares for $1.50 each; H.C. Wainwright & Co. acted as exclusive placement agent

1/30/15

Macrophage Therapeutics Inc. (unit of Navidea Biopharma-ceuticals Inc.)

Investment

N/A

$2.5

Navidea entered a non-binding term sheet for an initial round of standalone financing for its Macrophage business unit, which will be incorporated as a subsidiary; the initial investment is being proposed by Navidea director and newly named Macrophage Therapeutics CEO, Michael Goldberg, who intends to lead a small group of accredited investors to complete the financing, raising $2.5M for a 0.5% ownership

1/22/15

Minerva Neurosciences Inc. (Waltham, Mass.)

Debt facility

N/A

$15

Minerva entered a $15M debt facility with Oxford Finance LLC and Silicon Valley Bank

1/22/15

Tapimmune Inc. (Seattle)

Registered direct placement

7.32U

$1.46

Tapimmune entered a definitive agreement with institutional investors for a registered direct placement of 7.32M units at $0.20 apiece, with each unit consisting of one share of common stock and one of each of series A warrants to purchase up to an aggregate of 7.32M shares of common stock with an exercise price of $1.50 per share; series B warrants to purchase up to an aggregate of 7.32M shares of common stock with an exercise price of $0.40 per share and a term of six months; series C warrants to purchase up to an aggregate of 7.32M shares of common stock with an exercise price of $1 per share and a term of five years; series D warrants to purchase up to an aggregate of 7.32M shares of common stock with an exercise price of $0.75 each; and series E warrants to purchase up to an aggregate of 7.32M shares of common stock with an exercise price of $1.25 each; if all of the above warrants are exercised in full for cash, gross proceeds would total about $34.4M

1/13/15

The Medicines Co. (Parsippany, N.J.)

Convertible senior notes offering

N/A

$350

The Medicines Co. priced a $350M private offering of convertible senior notes due 2022, an increase from the $300M offering it had previously announced; the notes will bear interest at a rate of 2.5% per year, payable semiannually; the company has granted to the initial purchasers a 30-day option to purchase up to an additional $50M in aggregate principal amount of the notes

1/9/15

Vaccinogen Inc. (Frederick, Md.)

Private placement

N/A

$10

Vaccinogen received the second $10M tranche – the first $10M closed in August – from a committed $80M funding round at a fixed price of $5.50 per share and backed by a Stockholm-based group known as The Investment Syndicate (TIS)

1/29/15

Xenoport Inc. (Santa Clara, Calif.)

Private placement of convertible senior notes due in 2022

N/A

$100

Xenoport priced $100M in 2.5% convertible senior notes due in 2022 in a private placement to qualified institutional buyers

1/30/15

Zosana Pharma Inc. (Fremont, Calif.)

Private placement

N/A

$15

Zosana raised $15M through Eli Lilly and Co. in a private placement conducted at the same time as its $49.5M IPO

1/27/15

Notes

This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Loan money is included in the total only when it is drawn down, if disclosed.

Currency conversions are based on exchange rates at the time of the deal.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

N/A = Not applicable; ND = Not disclosed.

This chart includes only biotech companies that develop therapeutics.